Encouraging Data on Eli Lilly's Necitumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 44 mins ago
Eli Lilly (LLY) announced encouraging results on its lung cancer candidate necitumumab from a phase III study.
Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S.
Merck KGaA Beats on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:20AM CDT
Merck KGaA (MKGAF) reported 1Q14 earnings per ADR of $3.17, up 13.6% year over year and ahead of the Zacks Consensus Estimate of $2.35.
Research and Markets: Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
Business Wire - Thu May 15, 7:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tb4tpx/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering.
Rejected Proposals, Earnings Results, and Financial Outlook - Analyst Notes on Allergan, Isis, Depomed, Lannett and Orexigen
PR Newswire - Thu May 15, 6:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Depomed Inc. (NASDAQ: DEPO), Lannett Company, Inc. (NYSE: LCI) and Orexigen Therapeutics, Inc. (NYSE: OREX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2490-100free.
Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
M2 - Thu May 15, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc9ntj/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering. PHARMACEUTICALS MANUFACTURERS (Global) Analysis provides a detailed overview of the PHARMACEUTICALS MANUFACTURERS (Global) market and delivers a comprehensive individual analysis on the top 200 companies, including ALLERGAN INC, A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE - S.R.L. and BOIRON SA. This report includes a wealth of information on the financial trends over the past four years. Latest PHARMACEUTICALS MANUFACTURERS (Global) analysis is ideal for anyone wanting to: - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance A quick glance of this PHARMACEUTICALS MANUFACTURERS (Global) report will tell you that 25 companies have a declining Plimsoll financial rating, while 47 have shown good sales growth. Each of the largest 200 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings For more information visit http://www.researchandmarkets.com/research/cc...aceuticals
Merck Continues to Divest Ophthalmology Products - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 4:00PM CDT
Merck (MRK) entered into an agreement with Santen Pharmaceutical Co. to divest its ophthalmology products.
Allergan Up 27.0% Since SmarTrend Uptrend Call (AGN)
Comtex SmarTrend(R) - Wed May 14, 11:06AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 4 weeks, Allergan has returned 27.03% as of today's recent price of $160.01.
Pershing Square Eyes Nonbinding Vote on Allergan Bid
at The Street - Wed May 14, 9:41AM CDT
Bill Ackman's activist hedge fund Pershing Square Capital Management expects Allergan shareholders will have an opportunity as soon as next month to consider its proposal to have the Irvine, Calif.-based company engage in discussions over Canada's...
Healthcare Buyout Mania: Now What?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed May 14, 9:32AM CDT
It feels like there's nothing to talk about in the pharmaceutical space these days other than the latest M&A bid. Just in the last day and a half, investors have seen news on five completed or proposed transactions. And I doubt the deal-making is...
Dr. Reddy's Misses Q4 Earnings Ests, Beats on Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:30AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter 2014 earnings per ADS of 47 cents, missing the Zacks Consensus Estimate of 52 cents.
Athersys Reports Wider-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:04AM CDT
Athersys, Inc.'s (ATHX) first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents.
Global Hyaluronic Acid Products Market Product Trends and Forecasts, 2019: Single-Injection, Three-Injection Cycle and Five-Injection Cycle Analysis
M2 - Wed May 14, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snvprr/hyaluronic_acid) has announced the addition of the "Hyaluronic Acid Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. Hyaluronic acid (HA) is a unique non-sulfated glycosaminoglycan, distributed throughout the body in connective tissues, epithelial and neural tissues. Hyaluronic acid contributes significantly to cell proliferation and migration and is observed to be an integral component of the extracellular matrix. Hyaluronic acid has wide number of applications such as orthopedic surgery, rheumatology, ophthalmology, otolaryngology, dermatology and plastic surgery, wound healing and drug delivery. Hyaluronic acid products are segmented on the basis of treatment regimen into single-injection, three-injection cycle and five-injection cycle products. In addition, HA injectable can be utilized in a range of applications such as osteoarthritis, dermal fillers, ophthalmic surgery and vesicoureteral reflux (VUX). The major factors driving this market are increasing geriatric population globally, high awareness about anti-aging procedures, patient's preference for the treatment with minimum side-effects and rising demand for minimally invasive surgical procedures. In products segment, five-injection cycle products is the largest marketsegment and single-injection market segment is growing with highest CAGR during forecast period from 2013 to 2019. Hyaluronic acid products market is observing a global shift in usage of five-injection cycle to single-injection cycle treatment as there has been a considerable change in preference of patients towards short duration treatment. This shift in preference is mainly related to convenience of patients as they try to avoid side-effects such as redness, inflammation and itching experienced after every treatment and five-injection cycle is a prolonged treatment compared to single-injection. Dermal fillers is the largest market closely followed by osteoarthritis market and vesicoureteral reflux (VUR) applications market. VUR application market for hyaluronic acid products is growing at a highest CAGR during the forecast period from 2013 to 2019. The segment is mainly driven by aging population, high demand for minimally invasive surgical treatments and high awareness about beauty enhancements. Report Scope Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Hyaluronic Acid Products Market, by Geography - North America - Europe - Asia-Pacific - Rest of the World (RoW) Companies Mentioned - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sn...ronic_acid
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Global Diabetic Retinopathy Clinical Trials Report 2014
M2 - Wed May 14, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t9jfks/diabetic) has announced the addition of the "Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" report to their offering. Diabetic Retinopathy Global Clinical Trials Review, H1, 2014 provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Retinopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Retinopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Novartis AG - Pfizer Inc. - Valeant Pharmaceuticals International, Inc. - Allergan, Inc. - Takeda Pharmaceutical Company Limited - Eli Lilly and Company - AstraZeneca PLC - BCN Peptides, S.A. - National Eye Institute - University of Sao Paulo - National Taiwan University Hospital - Association for Innovation and Biomedical Research on Light and Image - Medical University of Vienna - Moorfields Eye Hospital NHS Foundation Trust - Diabetic Retinopathy Clinical Research Network - Shahid Beheshti University of Medical Sciences - HOSPITAL JUAREZ DE MEXICO - Federal University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/t9jfks/diabetic
Levadex (Migraine) - Forecast and Market Analysis to 2023
M2 - Wed May 14, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5vtkm/levadex) has announced the addition of the "Levadex (Migraine) - Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Levadex is being developed by Allergan as an acute therapy for migraine. Levadex is a member of the ergot alkaloids class of acute migraine treatment. It contains a reformulation of the drug dihydroergotamine mesylate (DHE) in a proprietary Tempo inhaler that allows DHE to be rapidly absorbed from the pleural mucosa into the systemic circulation. DHE has been used to treat migraine attacks for decades, administered by intravenous infusion or nasal sprays. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Levadex 9 Appendix For more information visit http://www.researchandmarkets.com/research/q5vtkm/levadex
Abbott's Promising Data on RADICAL Platform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 5:05PM CDT
Abbott Labs (ABT) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study.
Shire to Acquire Lumena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 4:00PM CDT
In a bid to strengthen its rare disease portfolio, Shire (SHPG) entered into an agreement to acquire privately-held Lumena Pharmaceuticals.
DirecTV and Green Mountain are big market movers
AP - Tue May 13, 3:28PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
S&P 500 Eclipses 1,900 for First Time, Dow Books Another All-Time High
at The Street - Tue May 13, 3:21PM CDT
The S&P 500 breaks above 1,900 for the first time and closes, along with the Dow, with a record high.